|Synonyms||TKI-258 Dilactic Acid|
|Description||ADX-47273 is a drug used in scientific research which acts as a positive allosteric modulator selective for the metabotropic glutamate receptor subtype mGluR5.|
Potent and selective antagonist for metabotropic glutamate receptor subtype 5 (mGluR5); Systemically active in vivo.
CTEP is a novel, long-acting, orally bioavailable allosteric antagonist of mGlu5 receptor (IC50=2.2 nM), showing >1000-fold selectivity over other mGlu receptor...
ADX-47273 is a drug used in scientific research which acts as a positive allosteric modulator selective for the metabotropic glutamate receptor subtype mGluR5.
VU-0483605, an isoindol derivative, has been found to be a mGluR1 positive allosteric modulator and probably be effective against schizophrenia. EC50: 356 and 3...
Raseglurant is a negative allosteric modulator of the mGlu5 receptor and derivative of MPEP. It can be used for the treatment of migraine, gastroesophageal refl...
LY-404,039, also known as pomaglumetad, is an amino acid analog drug that acts as a highly selective agonist for the metabotropic glutamate receptor group II su...
MPEP is a selective mGlu5 receptor antagonist with IC50 of 36 nM, exhibiting no appreciable activity at mGlu1b/2/3/4a/7b/8a/6 receptors.
Very selective nanomolar potent antagonist for group II mGlu receptors. Also a relatively potent antagonist for group III mGlu receptors at high nanomolar to lo...
JNJ-40411813 is a novel positive allosteric modulator of the metabotropic Glutamate 2 receptor (mGlu2R) with EC50 of 147 nM.
Glutamate, the major excitatory neurotransmitter in the brain, acts on both ionotropic and metabotropic glutamate receptors. Excessive metabotropic glutamate re...
BAY 36-7620 elective mGlu1 receptor non-competitive antagonist (IC50 = 0.16 μM) with inverse agonist activity.
ML337 is a Selective negative allosteric modulator of mGlu3 with IC50 value of 593 nM. It shows no activity at mGlu1, mGlu2 or mGlu4-8 at concentrations up to 3...
Dipraglurant is a mGlu5 receptor negative allosteric modulator. It is currently in phase II for the treatment of dyskinesia in Parkinson's disease.
VU0357121 is a novel positive allosteric modulator (PAM) of mGlu5 with EC50 of 33 nM, is inactive or very weakly antagonizing at other mGlu receptor subtypes.
FITM is a potent mGlu1 inhibitor (Ki = 2.5 nM) with great selectivity that does not disrupt mGlu5.
RG7090 is a negative modulator of metabotropic glutamate receptor subtype 5 (mGluR5; GRM5).
L-Glutamine is one of the 20 amino acids encoded by the standard genetic code.
CPPHA is a selective positive allosteric modulator of mGluR5 receptor. It is thought to act at a novel allosteric site and potentiates mGlu5 responses by a mech...